Iovance Biotherapeutics, Inc. (IOVA): Volume dodolan mangsa ngarep perusahaan

Logo grafis Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics (IOVA), a leader in FDA-approved TIL therapy, is attracting top specialists with ambitious stock options, while the GURU.Markets interface displays the company's projected sales dynamics, where 0.38 reflects the latest metric value. However, geopolitics are complicating global trials and biomaterial logistics, and the costs of implementing Amtagvi and scaling production are putting serious pressure on business margins.

Prakiraan pendapatan perusahaan: Iovance Biotherapeutics (IOVA) kanggo 04.07.2022 - 17.11.2026

IOVA (Iovance Biotherapeutics): rincian analitis lan laporan miturut indikator

- nilai saham lan prakiraan konsensus rega:
Ringkesan analisis perusahaan:Iovance Biotherapeutics, Inc.
Sampel barang Iovance Corp

This indicator measures the dynamics of expected operating income, allowing for the identification of speculative overheating of the asset by analyzing the speed of revenue reaction to external shocks. By assessing the sales volume potential of Iovance Biotherapeutics (IOVA) on the GURU.Markets platform, investors determine the entry point, which is critically important for Iovance Biotherapeutics (IOVA) given US intellectual property protections and the absence of geopolitical risks in cancer therapy development.

Pesaing langsung

Prakiraan pendapatan perusahaan ImmunityBio Inc (IBRX)|Volume dodolan mangsa ngarep perusahaan Immunocore PLC IMCR|Janux Therapeutics Inc - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume dodolan Arcus Corp RCUS|ZYME - Prakiraan pendapatan perusahaan|TNGX (tangotx.com) - Prakiraan pendapatan perusahaan|Immatics Biotechnologies (IMTX) - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Xencor Corp (XNCR)|Volume dodolan mangsa ngarep perusahaan CMPX|REPL - Prakiraan dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan LYEL (Lyell Immunopharma Inc)|Prakiraan volume pendapatan perusahaan IPHA|Prakiraan volume dodolan PYXS (Pyxis Oncology, Inc.)|Pendapatan mangsa ngarep perusahaan CGEN|iobiotech.com - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Sutro Biopharma, Inc|MiNK Therapeutics, Inc. (INKT) - Prakiraan pendapatan perusahaan|Werewolf Therapeutics Inc. - Pendapatan mangsa ngarep perusahaan|IMMX (Immix) - Prakiraan volume dodolan|Prakiraan volume dodolan ALX Oncology Holdings Inc.|Volume dodolan mangsa ngarep perusahaan CUE (Cue Biopharma Inc.)|PDSB: Pendapatan sing dikarepake perusahaan|Sonnet BioTherapeutics Holdings - Volume dodolan mangsa ngarep perusahaan|MAIABiotech.com (MAIA) - Volume dodolan sing dikarepake perusahaan|LIMN - Prakiraan pendapatan perusahaan|LVTX: Prakiraan pendapatan perusahaan|NXTC: Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Leap Therapeutics Inc (LPTX)|Volume dodolan mangsa ngarep perusahaan INTS|Prakiraan pendapatan perusahaan SNSE (senseibio.com)|Prakiraan pendapatan perusahaan Theriva Biologics (TOVX)|Prakiraan volume pendapatan perusahaan GRTS|Kineta Bio - Volume dodolan mangsa ngarep perusahaan|NEXI - Volume dodolan mangsa ngarep perusahaan|TSBX: Volume dodolan mangsa ngarep perusahaan|VCNX (Vaccinex, Inc.) - Prakiraan pendapatan perusahaan|Harpoon Tx (HARP) - Prakiraan pendapatan perusahaan